Citius Oncology (NASDAQ:CTOR) Announces Earnings Results

Citius Oncology (NASDAQ:CTOR) announced its quarterly earnings results on Friday. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.26), FiscalAI reports. The business had revenue of $1.67 million for the quarter, compared to the consensus estimate of $7.00 million.

Citius Oncology Stock Performance

Shares of NASDAQ CTOR opened at $0.96 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.32 and a current ratio of 0.83. The company has a market cap of $85.04 million, a P/E ratio of -2.05 and a beta of 3.56. The firm’s fifty day moving average is $0.80 and its two-hundred day moving average is $1.07. Citius Oncology has a 52-week low of $0.49 and a 52-week high of $6.19.

Institutional Trading of Citius Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE increased its holdings in Citius Oncology by 5,256.9% in the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock valued at $37,000 after acquiring an additional 8,411 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Citius Oncology in the 3rd quarter worth about $36,000. Geode Capital Management LLC increased its holdings in shares of Citius Oncology by 179.0% in the 2nd quarter. Geode Capital Management LLC now owns 57,297 shares of the company’s stock worth $249,000 after buying an additional 36,758 shares during the last quarter. OMERS ADMINISTRATION Corp bought a new stake in shares of Citius Oncology in the 4th quarter worth about $104,000. Finally, Jane Street Group LLC bought a new stake in shares of Citius Oncology in the 2nd quarter worth about $465,000. 70.52% of the stock is currently owned by institutional investors.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.